We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+16.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.8B
AUM Growth
+$1.2B
Cap. Flow
+$591M
Cap. Flow %
8.68%
Top 10 Hldgs %
38.38%
Holding
154
New
24
Increased
52
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$204M
2
PRGO icon
Perrigo
PRGO
+$111M
3
ABBV icon
AbbVie
ABBV
+$99.2M
4
CELG
Celgene Corp
CELG
+$71.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$70.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$169M
2
ELV icon
Elevance Health
ELV
+$69M
3
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$56.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$53.1M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.58%
2 Financials 1.18%
3 Technology 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$166B
$375M 5.51%
4,992,600
+214,800
+4% +$15M
BIIB icon
2
Biogen
BIIB
$32.1B
$306M 4.5%
1,095,100
+68,700
+7% +$17.8M
CELG
3
DELISTED
Celgene Corp
CELG
$297M 4.36%
3,514,200
+900,200
+34% +$71.2M
BMY icon
4
Bristol-Myers Squibb
BMY
$130B
$290M 4.27%
5,465,000
+261,000
+5% +$13.3M
AMGN icon
5
Amgen
AMGN
$213B
$287M 4.22%
2,515,300
-114,300
-4% -$13M
RLYP
6
DELISTED
RELYPSA INC COM
RLYP
$249M 3.65%
+9,941,549
New +$204M
INCY icon
7
Incyte
INCY
$25.6B
$206M 3.03%
4,069,000
-404,000
-9% -$17.6M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$73.1B
$203M 2.99%
738,800
+225,700
+44% +$64.9M
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$199M 2.93%
6,247,000
+1,678,000
+37% +$50.7M
ABBV icon
10
AbbVie
ABBV
$469B
$199M 2.92%
3,760,900
+2,018,900
+116% +$99.2M
VTRS icon
11
Viatris
VTRS
$20.9B
$183M 2.69%
4,214,500
-834,500
-17% -$34.3M
HCA icon
12
HCA Healthcare
HCA
$90.7B
$179M 2.64%
3,758,000
+705,000
+23% +$32.6M
ILMN icon
13
Illumina
ILMN
$29.4B
$177M 2.6%
1,641,510
+3,084
+0.2% +$282K
A icon
14
Agilent Technologies
A
$39.9B
$173M 2.54%
4,218,605
+1,078,697
+34% +$41M
TMO icon
15
Thermo Fisher Scientific
TMO
$215B
$171M 2.51%
1,534,200
-11,800
-0.8% -$1.17M
MRK icon
16
Merck
MRK
$324B
$127M 1.87%
2,669,256
-3,698,392
-58% -$169M
AGN
17
DELISTED
Allergan plc
AGN
$120M 1.76%
713,000
+237,900
+50% +$37.2M
PRGO icon
18
Perrigo
PRGO
$1.44B
$119M 1.74%
+773,000
New +$111M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$118M 1.74%
1,734,934
-416,673
-19% -$24.1M
ITMN
20
DELISTED
INTERMUNE INC
ITMN
$113M 1.67%
7,697,000
+4,809,400
+167% +$66.5M
PFE icon
21
Pfizer
PFE
$144B
$109M 1.6%
3,744,862
-482,100
-11% -$14M
PODD icon
22
Insulet
PODD
$11.7B
$107M 1.57%
2,888,500
+36,000
+1% +$1.33M
IPXL
23
DELISTED
Impax Laboratories, Inc.
IPXL
$107M 1.57%
4,237,600
+951,900
+29% +$21.2M
SHPG
24
DELISTED
Shire pic
SHPG
$102M 1.5%
724,000
+33,100
+5% +$4.35M
BMRN icon
25
BioMarin Pharmaceuticals
BMRN
$12B
$99.5M 1.46%
1,414,100
-167,600
-11% -$11.4M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2013 Portfolio in Review

As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $591M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 84% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Merck, an estimated $169M trimmed.

  • OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
  • OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
  • OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
  • OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
  • OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
  • OrbiMed opened 24 new positions and closed 34 in Q4 2013.
  • OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.